EP3060220A1 - Compositions for oral administration of zoledronic acid or related compounds for treating disease - Google Patents
Compositions for oral administration of zoledronic acid or related compounds for treating diseaseInfo
- Publication number
- EP3060220A1 EP3060220A1 EP14856165.7A EP14856165A EP3060220A1 EP 3060220 A1 EP3060220 A1 EP 3060220A1 EP 14856165 A EP14856165 A EP 14856165A EP 3060220 A1 EP3060220 A1 EP 3060220A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- zoledronic acid
- dosage form
- oral dosage
- administered
- disodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Bisphosphonate compounds are potent inhibitors of osteoclast activity, and are used clinically to treat bone-related conditions such as osteoporosis and Paget's disease of bone; and cancer-related conditions including multiple myeloma, and bone metastases from solid tumors. They generally have low oral bioavailability.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in an area under the plasma concentration curve (AUC) of zoledronic acid of about 50 ng hr/mL to about 700 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- AUC area under the plasma concentration curve
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 300 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.4 hr to about 1 hr.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 12 to about 50 for the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 30 for the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 6 to about 20 for the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 5 to about 20 for the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 4 to about 20 for the particular species of mammal.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 12 hours that is about 0.5 ng/mL to about 5 ng/mL.
- Some embodiments include an oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 30 hours to about 100 hours.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the zoledronic acid is present in the oral dosage form in an amount that results in an AUC of zoledronic acid of about 50 ng hr/mL to about 700 ng hr/mL upon administration of the oral dosage form to the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the zoledronic acid is present in the oral dosage form in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 300 ng/mL upon administration of the oral dosage form to the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.4 hr to about 1 hr.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 12 to about 50 for the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 30 for the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 6 to about 20 for the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 5 to about 20 for the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 4 to about 20 for the mammal.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 12 hours that is about 0.5 ng/mL to about 5 ng/mL.
- Some embodiments include a method of treating a disease or condition related to bone, cancer, or pain, comprising administering an oral dosage form comprising zoledronic acid to a mammal in need thereof, wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 30 hours to about 100 hours.
- Some embodiments include a method of enhancing the oral bioavailability of zoledronic acid comprising orally administering a dosage form containing zoledronic acid in the disodium salt form.
- Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the bioavailability, in a mammal, of zoledronic acid in the disodium salt form is greater than the bioavailability of zoledronic acid in the diacid form would be in the same dosage form.
- Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 2000 ng « h/ml_ to a human being to which the dosage form is administered.
- Some embodiments include a dosage form comprising zoledronic acid in the disodium salt form, wherein the disodium salt form is present in a lower molar amount than would be present if the zoledronic acid were in the diacid form; and wherein the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.
- the treatment can also be effective using an oral dosage form that includes a bisphosphonate compound, such as zoledronic acid, wherein the bioavailability of the bisphosphonate is unenhanced, or is substantially unenhanced.
- a bisphosphonate compound such as zoledronic acid
- Some embodiments include a method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the mammal experiences significant pain relief more than 3 hours after administration of the dosage form.
- Some embodiments include a method of relieving pain associated with an arthritis comprising administering an oral dosage form containing zoledronic acid to a human being in need thereof.
- Some embodiments include a method of treating complex regional pain syndrome comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.
- Some embodiments include an oral dosage form comprising zoledronic acid, wherein the oral bioavailability of zoledronic acid is substantially unenhanced.
- the oral bioavailability in the dosage form is about 0.01 % to about 4%.
- Some embodiments include a pharmaceutical product comprising more than one unit of an oral dosage form described herein. In some embodiments, each unit of the oral dosage form contains about 1 mg to about 50 mg of zoledronic acid.
- Some embodiments include a method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.
- the mammal receives a total monthly dose of zoledronic acid that is about 800 mg/m 2 or less.
- the dosage form contains about 10 mg/m 2 to about 20 mg/m 2 based upon the body surface area of the mammal.
- Some embodiments include a method of relieving inflammatory pain comprising orally administering zoledronic acid to a mammal in need thereof.
- about 300 mg/m 2 to about 600 mg/m 2 of zoledronic acid is administered per month, based upon the body surface area of the mammal.
- about 50 mg/m 2 to about 600 mg/m 2 of zoledronic acid is administered per month, based upon the body surface area of the mammal.
- FIG. 1 is a plot of pain compression thresholds in a rat model of inflammatory pain using three different doses of zoledronic acid. Measurements were taken at baseline (BL) and at various time points after dosing on the days indicated.
- FIG. 2A is a graph depicting reversal of arthritis pain for two different doses of zoledronic acid in a rat model of arthritis pain.
- FIG. 2B is a graph depicting pain thresholds for two different doses of zoledronic acid in a rat model of arthritis pain.
- FIG. 3 is a graph summarizing the results for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.
- FIG. 4 depicts hindpaw pain thresholds for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.
- FIG. 5 depicts weight bearing for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.
- FIG. 6 depicts paw thickness change for vehicle and zoledronic acid treated rats in a rat model of complex regional pain syndrome.
- FIG. 7 depicts the aqueous solubility of disodium zoledronate tetrahydrate as compared to the diacid form of zoledronic acid.
- FIG. 8 depicts the plasma concentration of zoledronic acid in dogs over time after administration of 150 mg of the disodium salt form of zoledronic acid and the diacid form of zoledronic acid.
- FIG. 9 depicts the compressibility of dosage forms containing zoledronic acid in the disodium salt form as compared to the diacid form.
- Bisphosphonate compounds such as pamidronate or pamidronic acid, neridronate or neridronic acid, olpadronate or olpadronic acid, alendronate or alendronic acid, incadronate or incadronic acid, ibandronate or ibandronic acid, risedronate or risedronic acid, zoledronate or zoledronic acid, etidronate or etidronic acid, clodronate or clodronic acid, tiludronate or tiludronic acid, etc., may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including pain relief. This may be accomplished in many instances by administration of oral dosage forms. Generally, an oral dosage form comprising a bisphosphonate such as zoledronic acid is administered orally to a mammal, such as a human being, at least once, to treat a disease or condition, or to relieve pain.
- a mammal such as a human being
- treating broadly includes any kind of treatment activity, including the diagnosis, cure, mitigation, or prevention of disease in man or other animals, or any activity that otherwise affects the structure or any function of the body of man or other animals.
- An oral dosage form of a bisphosphonate such as zoledronic acid may be used to treat, or provide relief of, any type of pain including, but not limited to, inflammatory pain, arthritis pain, complex regional pain syndrome, lumbosacral pain, musculoskeletal pain, neuropathic pain, chronic pain, cancer- related pain, acute pain, postoperative pain, etc.
- pain relief may be palliative, or pain relief may be provided independent of improvement of the disease or condition or the underlying cause of the disease or condition. For example, although the underlying disease may not improve, or may continue to progress, an individual suffering from the disease may experience pain relief.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- the mammal being treated is not suffering from bone metastasis. In some embodiments, the mammal being treated is not suffering from cancer. In some embodiments, the mammal being treated is not suffering from osteoporosis.
- zoledronic acid or another bisphosphonate may be administered orally to relieve musculoskeletal pain including low back pain, and pain associated with rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, sero-negative (non- rheumatoid) arthropathies, non-articular rheumatism, peri-articular disorders, axial spondylarthritis including ankylosing spondylitis, Paget's disease, fibrous dysplasia, SAPHO syndrome, transient osteoarthritis of the hip, vertebral crush fractures, osteoporosis, etc.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- a bisphosphonate such as zoledronic acid, may also be used to treat bone fractures or to enhance the healing of bone fractures.
- zoledronic acid or another bisphosphonate may also be administered orally to relieve neuropathic pain, including diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, monoradiculopathies, phantom limb pain, and central pain.
- Other causes of neuropathic pain include cancer-related pain, lumbar nerve root compression, spinal cord injury, post-stroke pain, central multiple sclerosis pain, HIV-associated neuropathy, and radio-therapy or chemo-therapy associated neuropathy.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- zoledronic acid or another bisphosphonate may be administered orally to relieve inflammatory pain including musculoskeletal pain, arthritis pain, and complex regional pain syndrome.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- Examples of musculoskeletal pain include low back pain; and pain associated with vertebral crush fractures, fibrous dysplasia, osteogenesis imperfecta, Paget's disease of bone, transient osteoporosis, and transient osteoporosis of the hip.
- a bisphosphonate such as zoledronic acid
- zoledronic acid may also be used to treat low back pain, or other musculoskeletal or inflammatory conditions, having a change in bone that is detectable by MRI or another medical imaging instrument.
- a bisphosphonate such as zoledronic acid
- Modic changes can be classified into various types including type 1 (M1 ), type 2 (M2), and type 3 (M3) lesions or changes, any of which may be treated using a bisphosphonate such as zoledronic acid.
- VESCs may be found in patients with different types of low back pain including but not limited to spondylitis, trauma, spondyloarthropathies including ankylosing spondylitis, Schmorl's nodes, fracture, tumor, and spinal cord infarction. Lesions in ankylosing spondylitis include osteitis and spondylodiscitis which can be detected using MRI or another medical imaging instrument.
- a bisphoshosphonate such as zoledronic acid may also be used to treat osteoarthritis of the knee, such as osteoarthritis of the knee associated with bone marrow lesions (BML), including BML that may be detected using MRI or another medical imaging instrument.
- BML bone marrow lesions
- a bisphosphonate such as zoledronic acid
- BME bone marrow edema
- Arthritis refers to inflammatory joint diseases that can be associated with pain.
- arthritis pain include pain associated with osteoarthritis, erosive osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, sero-negative (non-rheumatoid) arthropathies, non-articular rheumatism, peri-articular disorders, neuropathic arthropaties including Charcot's foot, axial spondylarthritis including ankylosing spondylitis, and SAPHO syndrome.
- a human being that is treated for a disease or condition such as an inflammatory condition, e.g. arthritis, by an oral dosage form of zoledronic acid
- a disease or condition such as an inflammatory condition, e.g. arthritis, by an oral dosage form of zoledronic acid
- a human being that is treated for a disease or condition such as an inflammatory condition, e.g. arthritis, by an oral dosage form of zoledronic acid, has suffered from the arthritis for at least 1 month, at least 2 months, at least 6 months, or at least 1 year.
- a disease or condition such as an inflammatory condition, e.g. arthritis, by an oral dosage form of zoledronic acid
- the disease or condition such as an inflammatory condition, e.g. arthritis, affects a knee, an elbow, a finger, a wrist, a shoulder, or a hip.
- an inflammatory condition e.g. arthritis
- zoledronic acid or another bisphosphonate may be administered orally to relieve complex regional pain syndrome, such as complex regional pain syndrome type I (CRPS-I), complex regional pain syndrome type II (CRPS-II), CRPS-NOS, or another type of CRPS.
- CRPS is a type of inflammatory pain.
- CRPS can also have a neuropathic component.
- Complex regional pain syndrome is a debilitating pain syndrome. It is characterized by severe pain in a limb accompanied by edema, and autonomic, motor and sensory changes.
- a mammal such as a human being, experiences significant pain relief at least about 3 hours, at least about 6 hours, at least about 12 hours, at least about 24 hours, at least about 48 hours, at least about one week, at least about 2 weeks, or at least about 3 weeks after administration of an oral dosage form comprising zoledronic acid.
- a mammal such as a human being, experiences significant pain relief during at least part of the time from about 3 hours to about 2 weeks, about 3 hours to about 3 weeks, about 3 hours to about 24 hours, about 6 hours to about 2 weeks, or about 6 hours to about 24 hours, about 3 days to about 2 weeks, about 6 days to about 2 weeks, after administration of an oral dosage form comprising zoledronic acid.
- a first oral dosage form comprising zoledronic acid is administered and a second oral dosage form comprising oral zoledronic acid is administered.
- the timing of the administration of the two dosage forms may be such that, with respect to the first oral dosage form, the second oral dosage with respect to the first oral dosage form, the second oral dosage form is administered at 5 x Tmax or greater (e.g., if T max is 1 hour, at 5 hours or later), at least 10 x T max or greater, at least about 15 x T max or greater, at least about 20 x T max or greater, at least about 50 x T max or greater, or at least about 200 x T max or greater, wherein T max is the time of maximum plasma concentration for the first oral dosage form.
- Some embodiments include treatment of a condition recited herein, such as inflammatory pain, arthritis, or complex regional pain syndrome, wherein the treatment comprises either: administering only one dosage form to a mammal to treat the condition, or administering a first dosage form to the mammal, followed by administering a second dosage form to the mammal. If two or more dosage forms are administered, the second oral dosage form is administered before the maximum pain relieving effect of the first oral dosage form is achieved, or before a peak in the pain relieving effect of the first oral dosage form is experienced by a mammal, receiving the dosage form. In some embodiments, the second oral dosage form is administered before an observable pain relieving effect is achieved. In some embodiments, the second dosage form is administered about 12 hours to about 60 days, about 24 hours to about 28 days, about 24 hours to about 7 days, about 24 hours to about 14 days, or about 24 hours to about 21 days, after the first dosage form is administered.
- Some embodiments include treatment of a condition recited herein, such as inflammatory pain, arthritis, or complex regional pain syndrome, wherein the treatment comprises administering a first dosage form to the mammal, followed by administering a second dosage form to the mammal, wherein the second dosage form is administered after the maximum pain relieving effect of the first oral dosage form is achieved, and the second oral dosage form is administered while the mammal is still experiencing pain relief from the first oral dosage form, or while the pain relieving effect from the first oral dosage form is observable.
- the second dosage form is administered about 12 hours to about 60 days, about 24 hours to about 28 days, about 24 hours to about 7 days, about 24 hours to about 14 days, or about 24 hours to about 21 days, after the first dosage form is administered.
- Zoledronic acid or another bisphosphonate may also be administered orally to relieve cancer-related pain, including pain associated with multiple myeloma and bone metastases from solid tumors.
- zoledronic acid is used to treat pain that is not cancer- related pain.
- zoledronic acid may be used to treat pain that is not associated with multiple myeloma, bone metastasis from solid tumors, hypercalcemia of malignancy, giant cell tumor of bone, blood cancers or leukemias, or solid tumors or cancers.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- oral administration of zoledronic acid or another bisphosphonate may also be useful to treat diseases or conditions that may or may not include a pain component.
- zoledronic acid or another bisphosphonate may be useful to treat any of the pain conditions or types of conditions listed above, including treatment that does not simply relieve the pain of those conditions, and treatment that is carried out in such a way that the condition is treated without pain relief occurring.
- zoledronic acid or another bisphosphonates may be used to treat a disease or condition such as a metabolic disease or condition; an inflammatory disease or condition, including an inflammatory disease or condition that is not associated with pain; a cancer disease or condition; a neurological disease or condition; etc.
- a disease or condition such as a metabolic disease or condition; an inflammatory disease or condition, including an inflammatory disease or condition that is not associated with pain; a cancer disease or condition; a neurological disease or condition; etc.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- oral administration of zoledronic acid or another bisphosphonate may also be useful to treat complex regional pain syndrome, rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, axial spondyloarthritis including ankylosing spondylitis, acute vertebral crush fracture, fibrous dysplasia, SAPHO syndrome, osteoporosis, transient osteoporosis, or transient osteoporosis of the hip.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- oral administration of zoledronic acid or another bisphosphonate may also be useful to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, Paget's disease of bone, giant cell tumor of bone, blood cancers or leukemias, or solid tumors or cancers.
- enhanced bioavailability of the zoledronic acid may be achieved in treating one of these conditions by administering a dosage form comprising zoledronic acid in the form of a disodium salt. This may allow a reduced molar amount of the disodium salt to be used as compared to what would be used with the diacid form.
- a bisphosphonate such as zoledronic acid may be used to treat otosclerosis.
- Zoledronic acid has the structure shown below, and is also referred to as zoledronate.
- any reference to a compound herein, such as zoledronic acid, by structure, name, or any other means, includes pharmaceutically acceptable salts, such as the disodium salt; alternate solid forms, such as polymorphs, solvates, hydrates, etc.; tautomers; or any other chemical species that may rapidly convert to a compound described herein under conditions in which the compounds are used as described herein.
- zoledronic acid is administered in a dosage form comprising a salt form, such as a salt of a dianion of zoledronic acid.
- zoledronic acid is administered in a dosage form comprising a disodium salt form of zoledronic acid.
- zoledronic acid is administered in a sodium salt form, such as a monosodium salt, a disodium salt, a trisodium salt, etc.
- use of the disodium salt may be desirable.
- the disodium salt is much more soluble in water than the diacid form.
- the disodium salt can be easier to work with than the diacid form.
- the sodium salt may be more bioavailable and/or more rapidly absorbed when taken orally as compared to the diacid form.
- Some oral dosage forms comprising zoledronic acid have a dose of zoledronic acid and a configuration suitable for a particular species of mammal, e.g. dog, rat, human, etc. Such a dosage form may have zoledronic acid present in an amount that results in a desired range for an area under the plasma concentration curve (AUC) of zoledronic acid in that particular species of mammal.
- AUC area under the plasma concentration curve
- the dose of zoledronic acid and a configuration of the oral dosage form may result in an AUC of zoledronic acid of about 1 ng hr/mL to about 700 ng hr/mL, about 3 ng hr/mL to about 30 ng hr/mL, about 3 ng hr/mL to about 10 ng hr/mL, about 50 ng hr/mL to about 700 ng hr/mL, about 130 ng hr/mL to about 180 ng hr/mL, about 300 ng hr/mL to about 450 ng hr/mL, about 300 ng hr/mL to about 350 ng hr/mL, about 300 ng hr/mL to about 310 ng hr/mL, about 340 ng hr/mL to about 350 ng hr/mL, about 370 ng hr/mL to about 420 ng hr
- the AUC refers to the AUC calculated to the last measured concentration (AUC (0 - t )) and extrapolated to infinity (AUC (0 -in f) )-
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may have zoledronic acid present in an amount that results in a C max of zoledronic acid of about 0.2 ng/mL to about 300 ng/mL, about 0.5 ng/mL to about 5 ng/mL, about 5 ng/mL to about 300 ng/mL, about 5 ng/mL to about 50 ng/mL, about 20 ng/mL to about 50 ng/mL, about 30 ng/mL to about 50 ng/mL, about 50 ng/mL to about 200 ng/mL, about 50 ng/mL to about 150 ng/mL, about 80 ng/mL to about 120 ng/mL, about 90 ng/mL to about 100 ng/mL, about 50 ng/mL to about 200 ng/mL, about 40 ng/mL, about 90 ng
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.4 hr to about 1 hr, about 0.5 hr, or about 0.75 hr, or any T max in a range bounded by, or between, any of these values.
- the oral bioavailability of zoledronic acid may be enhanced by orally administering the zoledronic acid in the disodium salt form.
- the bioavailability of zoledronic acid may be improved by at least about 10%, at least about 20%, at least about 30%, at least about 50%, and/or up to about 100%, or up to about 200%, as compared to administration of zoledronic acid in the diacid form.
- a dosage form may contain, or a mammal, such as a human being, may receive, on a molar basis, less of the disodium salt form of zoledronic acid than would otherwise be administered of the diacid form of zoledronic acid.
- a dosage form may contain, or a mammal may receive, at least about 10 mole% less, at least about 20 mole% less, at least about 40 mole% less, at least about 50 mole% less, and/or up to about 90 mole% less or 95 mole% less, of the disodium salt form as compared the amount of the diacid form of zoledronic acid that would otherwise be administered, such as a molar amount that would be administered of zoledronic acid in the diacid form in order to achieve the same plasma levels of zoledronic acid.
- a dosage form contains, or a mammal (such as a human being) is administered, an amount of the disodium salt form, on a molar basis, that has a value of about 0.8n d to about 1.2n d or about 0.9n d to about 1.1 n d , wherein:
- n d (b a /b d )(n a )
- b a is the bioavailability of the diacid form
- b d is the bioavailability of the disodium salt form
- n a is the number of moles of the diacid that would be administered in a dosage form containing the diacid form of zoledronic acid.
- the disodium salt is administered in an amount that has a value of about n d .
- the bioavailability of the zoledronic acid in the disodium salt form is sufficiently high that, if the drug is administered to a mammal, at least as much zoledronic acid is present in the blood of the mammal as would be present if zoledronic acid were administered in the diacid form.
- the disodium salt form is present in a lower molar amount than would be present if the zoledronic acid were in the diacid form; and the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.
- the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve (AUC) of zoledronic acid of about 4 ng « h/ml_ to about 2000 ng « h/ml_ to the mammal each time the zoledronic acid in the disodium salt is administered.
- AUC area under the plasma concentration curve
- the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 100 ng « h/ml_ to about 2000 ng « h/ml_, about 100 ng « h/ml_ to about 1000 ng « h/ml_, about 500 ng « h/ml_ to about 1000 ng « h/ml_, or about 500 ng « h/ml_ to about 700 ng « h/ml_ in the mammal to which the dosage form is administered.
- This amount may be suitable for administration of the oral dosage form about every 3 to 4 weeks.
- the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 20 ng « h/ml_ to about 700 ng « h/ml_, about 50 ng « h/ml_ to about 500 ng « h/ml_, or about 100 ng « h/ml_ to about 200 ng « h/ml_, in the mammal to which the dosage form is administered.
- This amount may be suitable for weekly administration of the oral dosage, or for administration of 3 to 5 individual dosages during a month.
- the individual dosages could be given at regular intervals, given during the first week, or at any other schedule that provides 3 to 5 dosages during the month.
- the zoledronic acid in the disodium salt form is present in an amount such that the oral dosage form provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 100 ng « h/ml_, about 10 ng « h/ml_ to about 50 ng « h/ml_, or about 10 ng « h/ml_ to about 30 ng « h/ml_, in the mammal to which the dosage form is administered. This amount may be suitable for daily administration of the oral dosage form.
- Oral administration of zoledronic acid can result in more sustained plasma levels of the drug as compared to parenteral modes of administration, such intravenous or subcutaneous.
- the amount of zoledronic acid in the plasma can be significantly higher for oral administration of the disodium salt about 24 hours or 48 hours, or longer, after administration.
- oral zoledronic acid has a 24 hour sustained plasma level factor of about 1 or higher, such as about 1 to about 10, about 1 to about 5, about 3 to about 5, or about 3 to about 4.
- an orally administered dosage form of zoledronic acid has a 24 hour sustained plasma level factor or a 48 hour sustained plasma level factor that is higher, such as at least 1.2 times, at least about 2 times, at least about 5 times, about 1.2 times to about 20 times, about 2 times to about 15 times, about 5 times to about 10 times, or about 8 to about 15 times that of intravenously administered zoledronic acid.
- a "sustained plasma level factor," p f is determined by the equation:
- C max is the maximum plasma concentration of zoledronic acid after it is administered and C t is the plasma concentration of zoledronic acid at the time of interest, such as 24 hours.
- the C max can be about the Co, or the concentration right after injection of the entire amount of the drug into the body.
- Sustained plasma level factors can also be obtained for other times, such as 48 hours, by using the plasma concentration of zoledronic acid for C t in the equation above. For example, if the maximum plasma level of zoledronic acid after administration is 1000 ng/mL and the plasma level of zoledronic acid at 24 hours is 1 ng/mL, the 24 hour sustained plasma level factor is 1.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 12 to about 50, about 20 to about 40, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 33, about 30, about 35, or any 12 hour sustained plasma level factor in a range bounded by, or between, any of these values, for the particular species of mammal.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 30, about 10 to about 20, about 10 to about 15, about 12 to about 15 or 16, about 15 to about 20, about 14, about 12, about 15, or any 24 hour sustained plasma level factor in a range bounded by, or between, any of these values, for the particular species of mammal.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 6 to about 20, about 8 to about 15, about 9 to about 12 or 13, about 8 to about 10, about 1 1 to about 13, about 9, about 13, or any 24 hour sustained plasma level factor in a range bounded by, or between, any of these values, for the particular species of mammal.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 5 to about 20, about 6 to about 15, about 7 or 8 to about 12 or 13, about 8 to about 10, about 1 1 to about 13, about 8, about 12, or any 48 hour sustained plasma level factor in a range bounded by, or between, any of these values, for the particular species of mammal.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 4 to about 20, about 5 to about 10, about 5 or 6 to about 10 or 1 1 , about 5 to about 6, about 9 to about 10, about 6, about 10, or any 72 hour sustained plasma level factor in a range bounded by, or between, any of these values, for the particular species of mammal.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 12 hours that is about 0.5 ng/mL to about 5 ng/mL, about 1 ng/mL to about 3 ng/mL, about 1 ng/mL to about 2 ng/mL, about 2 ng/mL to about 3 ng/mL, about 3 ng/mL to about 4 ng/mL, about 1.2 ng/mL, about 2.6 ng/mL, about 3.2 ng/mL, or any plasma concentration in a range bounded by, or between, any of these values.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 24 hours that is about 0.2 ng/mL to about 2 ng/mL, about 0.5 ng/mL to about 1.5 ng/mL, about 0.5 ng/mL to about 1 ng/mL, about 1 ng/mL to about 1.5 ng/mL, about 0.5 ng/mL, about 1.0 ng/mL, about 1.4 ng/mL, or any plasma concentration in a range bounded by, or between, any of these values.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 36 hours that is about 0.1 ng/mL to about 2 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about 0.2 ng/mL to about 0.5 ng/mL, about 0.5 ng/mL to about 1 ng/mL, about 1 ng/mL to about 1.3 ng/mL, about 0.3 ng/mL, about 0.8 ng/mL, about 1.1 ng/mL, or any plasma concentration in a range bounded by, or between, any of these values.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 48 hours that is about 0.1 ng/mL to about 2 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about 0.2 ng/mL to about 0.5 ng/mL, about 0.5 ng/mL to about 0.9 ng/mL, about 0.9 ng/mL to about 1.3 ng/mL, about 0.3 ng/mL, about 0.7 ng/mL, about 1.1 ng/mL, or any plasma concentration in a range bounded by, or between, any of these values.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 72 hours that is about 0.2 ng/mL to about 1 ng/mL, about 0.2 ng/mL to about 1.5 ng/mL, about 0.1 ng/mL to about 0.3 ng/mL, about 0.3 ng/mL to about 0.6 ng/mL, about 0.6 ng/mL to about 1 ng/mL, about 0.2 ng/mL, about 0.5 ng/mL, about 0.9 ng/mL, or any plasma concentration in a range bounded by, or between, any of these values.
- An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal may be configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 30 hours to about 100 hours, about 40 hours to about 60 hours, about 40 hours to about 50 hours, about 50 hours to about 60 hours, about 42 hours, about 51 hours, about 59 hours, or any half-life in a range bounded by, or between, any of these values.
- the "elimination half-life” refers to the apparent first-order terminal plasma elimination half-life, obtained by non-compartmental analysis using Win-Nonlin.
- a terminal plasma elimination half-life is the time required to reduce the plasma concentration to half after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose.
- terminal plasma elimination half-life can be affected by absorption of the drug, as well as plasma clearance and extent of distribution.
- the disodium salt form of zoledronic acid provides an enhancement to bioavailability, as compared to the diacid form of zoledronic acid, which adds to any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form.
- the disodium salt form of zoledronic acid provides an enhancement to bioavailability, as compared to the diacid form of zoledronic acid, which is greater than any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form.
- the disodium salt form of zoledronic acid may be administered in a dosage form that is substantially free of bioavailability-enhancing agents.
- a dosage form comprising a disodium salt of zoledronic acid is a solid.
- a dosage form comprising a disodium salt of zoledronic acid is used to treat an inflammatory condition.
- a dosage form comprising a disodium salt of zoledronic acid is used to treat arthritis.
- a dosage form comprising a disodium salt of zoledronic acid is used to treat complex regional pain syndrome.
- zoledronic acid is in a form that has an aqueous solubility, meaning the solubility in water, greater than 1 % (w/v), about 5% (w/v) to about 50% (w/v), about 5% (w/v) to about 20% (w/v), about 10% (w/v) to about 15% (w/v), or about 12% (w/V) to about 13% (w/v),
- the disodium salt form of zoledronic acid can be more compressible than the diacid form of zoledronic acid. This can make it easier for a dosage form to have a desired hardness. It can also make it easier to increase the drug load, so that a smaller tablet can be given for a given dosage strength, in some embodiments, a solid dosage form of zoledronic acid, such as the diacid form of zoledronic acid or the disodium salt form of zoledronic acid, can have a hardness of about 5 kPa to about 20 kPa or about 5 kPa to about 14 kPa.
- Zoledronic acid or another bisphosphonate may be combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described, for example, in Remington's Pharmaceutical Sciences, 2005, the disclosure of which is hereby incorporated herein by reference, in its entirety.
- the relative proportions of active ingredient and carrier may be determined, for example, by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.
- Zoledronic acid or another bisphosphonate may be administered by any means that may result in the contact of the active agent(s) with the desired site or site(s) of action in the body of a patient.
- the compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents.
- they may be administered as the sole active agents in a pharmaceutical composition, or they can be used in combination with other therapeutically active ingredients.
- Zoledronic acid or another bisphosphonate may be administered to a human patient in a variety of forms adapted to the chosen route of administration, e.g., orally, rectally, or parenterally.
- Parenteral administration in this respect includes, but is not limited to, administration by the following routes: pulmonary, intrathecal, intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, transepithelial including transdermal, sublingual and buccal; topically; nasal inhalation via insufflation; and rectal systemic.
- the effective amount of zoledronic acid or another bisphosphonate will vary depending on various factors known to the treating physicians, such as the severity of the condition to be treated, route of administration, formulation and dosage forms, physical characteristics of the bisphosphonate compound used, and age, weight and response of the individual patients.
- the amount of zoledronic acid or another bisphosphonate in a therapeutic composition may vary.
- some liquid compositions may comprise about 0.0001 % (w/v) to about 50% (w/v), about 0.01 % (w/v) to about 20% (w/v), about 0.01 % to about 10% (w/v), about 0.001 % (w/v) to about 1 % (w/v), about 0.1 % (w/v) to about 0.5% (w/v), about 1 % (w/v) to about 3% (w/v), about 3% (w/v) to about 5% (w/v), about 5% (w/v) to about 7% (w/v), about 7% (w/v) to about 10% (w/v), about 10% (w/v) to about 15% (w/v), about 15% (w/v) to about 20% (w/v), about 20% (w/v) to about 30% (w/v), about 30% (w/v) to about 40% (w/v), or
- Some solid compositions may comprise at least about 5% (w/w), at least about 10% (w/w), at least about 20% (w/w), at least about 50% (w/w), at least about 70% (w/w), at least about 80%, about 10% (w/w) to about 30% (w/w), about 10% (w/w) to about 20% (w/w), about 20% (w/w) to about 30% (w/w), about 30% (w/w) to about 50% (w/w), about 30% (w/w) to about 40% (w/w), about 40% (w/w) to about 50% (w/w), about 50% (w/w) to about 80% (w/w), about 50% (w/w) to about 60% (w/w), about 70% (w/w) to about 75% (w/w), about 70% (w/w) to about 80% (w/w), or about 80% (w/w) to about 90% (w/w) of zoledronic acid.
- Some solid dosage forms comprising a bisphosphonate, such as zoledronic acid may contain about 1 mg to about 5 mg or 8 mg of the bisphosphonate, and the total mass of the dosage form may be less than about 9 mg, about 10 mg, about 1 1 mg, or about 15 mg.
- Some solid dosage forms comprising a bisphosphonate, such as zoledronic acid may contain about 5 mg to about 10 mg or 15 mg of the bisphosphonate, and the total mass of the dosage form may be less than about 15 mg, about 17 mg, about 21 mg, or about 29 mg.
- Some solid dosage forms comprising a bisphosphonate, such as zoledronic acid may contain about 10 mg to about 50 mg or 80 mg of the bisphosphonate, and the total mass of the dosage form may be less than about 77 mg, about 85 mg, about 1 10 mg, or about 150 mg.
- Some solid dosage forms comprising a bisphosphonate, such as zoledronic acid may contain about 100 mg to about 200 mg or 290 mg of the bisphosphonate, and the total mass of the dosage form may be less than about 280 mg, about 315 mg, about 360 mg, about 430 mg, or about 570 mg.
- Some solid dosage forms comprising a bisphosphonate, such as zoledronic acid may contain about 200 mg to about 300 mg or 430 mg of the bisphosphonate, and the total mass of the dosage form may be less than about 430 mg, about 500 mg, about 570 mg, about 640 mg, or about 710 mg.
- oral dosage form(s) may contain about 0.005 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to about 10 mg, about 0.2 mg to about 5 mg, about 1 mg to about 500 mg, about 1 mg to about 50 mg, about 1 mg to about 75 mg, about 10 mg to about 250 mg, about 100 mg to about 300 mg, about 20 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 100 mg, about 30 mg to about 150 mg, about 1 mg to about 1 ,000 mg, about 10 mg to about 50 mg, about 10 mg to about 300 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 40 mg to about 150 mg, about 40 mg to about 220 mg, about 10 mg to about 600 mg, about 40 mg to about 600 mg, about 40 mg to about 2000 mg, about 40 mg to about 800 mg, about 25 mg to
- an oral dosage form may contain about 10 mg/m 2 to about 20 mg/m 2 , about 15 mg/m 2 to about 20 mg/m 2 , about 18 mg/m 2 , about 80 mg/m 2 to about 150 mg/m 2 , about 90 mg/m 2 to about 150 mg/m 2 , about 100 mg/m 2 to about 150 mg/m 2 of zoledronic acid, or any amount of zoledronic in a range bounded by, or between, any of these values. All dosage ranges or amounts expressed in mg/m 2 are based upon the body surface area of the mammal.
- the daily oral dose of zoledronic acid is about 0.005 mg to about 20 mg, about 0.1 mg to about 10 mg, about 0.5 mg to about 10 mg, about 0.2 mg to about 5 mg, or any amount of zoledronic acid in a range bounded by, or between, any of these values.
- the daily oral dose of zoledronic acid is less than about 35 mg/m 2 , less than about 30 mg/m 2 , less than about 25 mg/m'", about 1 mg/m 2 to about 35 mg/m'", about 1 mg/m 2 to about 30 mg/m 2 , about 1 .5 mg/m 2 to about 25 mg/m 2 , about 1 .8 mg/m 2 to about 20 mg/m 2 , about 10 mg/m 2 to about 20 mg/m 2 , about 10 mg/m 2 to about 30 mg/m 2 , about 15 mg/m 2 to about 20 mg/m 2 , about 18 mg/m 2 , or any amount of zoledronic acid in a range bounded by, or between, any of these values.
- the weekly oral dose of zoledronic acid is about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 10 mg to about 250 mg, about 100 mg to about 300 mg, about 10 mg to about 100 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 10 mg to about 300 mg, about 20 mg to about 150 mg, or about 30 mg to about 100 mg.
- the weeky oral dose of zoledronic acid is less than about 250 mg/m 2 , less than about 200 mg/m 2 , less than about 175 mg/m 2 , about 6 mg/m 2 to about 250 mg/m 2 , about 10 mg/m 2 to about 210 mg/m 2 , about 10 mg/m 2 to about 170 mg/m 2 , about 4 mg/m 2 to about 140 mg/m 2 , about 100 mg/m 2 to about 140 mg/m , about 126 mg/m 2 , or any amount of zoledronic acid in a range bounded by, or between, any of these values.
- the weekly oral dose may be given as a single dose, given once during the week, or may be given in 2, 3, 4, 5, 6, or 7 individual doses during the week.
- the monthly dose of zoledronic acid, or the amount of zoledronic acid that is administered over a period of a month is about 5000 mg or less, about 4000 mg or less, about 3000 mg or less, about 2000 mg or less, about 1000 mg or less, about 700 mg or less, about 600 mg or less, about 1 mg to about 4,000 mg, about 1 mg to about 1 ,000 mg, about 10 mg to about 1000 mg, about 50 mg to about 1000 mg, about 10 mg to about 600 mg, about 40 mg to about 600 mg, about 50 mg to about 600 mg, or about 100 mg to about 600 mg, about 40 mg to about 2000 mg, about 40 mg to about 800 mg, about 50 mg to about 800 mg, or about 100 mg to about 800 mg, about 40 mg to about 1000 mg, about 50 mg to about 1000 mg, or about 100 mg to about 1000 mg, or any monthly dose in a range bounded by, or between, any of these values.
- the monthly oral dose of zoledronic acid is less than about 1000 mg/m 2 , less than about 800 mg/m 2 , less than about 600 mg/m 2 , about 10 mg/m 2 to about 1000 mg/m 2 , about 50 mg/m 2 to about 800 mg/m 2 , about 70 mg/m 2 to about 700 mg/m 2 , about 100 mg/m 2 to about 700 mg/m 2 , about 100 mg/m 2 to about 600 mg/m 2 , about 50 mg/m 2 to about 200 mg/m 2 , about 300 mg/m 2 to about 600 mg/m 2 , about 450 mg/m 2 to about 600 mg/m 2 , about 300 mg/m 2 to about 1000 mg/m 2 , about 400 mg/m 2 to about 1000 mg/m 2 , about 500 mg/m 2 to about 1000 mg/m 2 , about 400 mg/m 2 to about 700 mg/m 2 , about 500 mg/m 2 to about 600 mg/m 2 , about 540 mg/m 2 , or any amount
- a monthly dose may be given as a single dose, or as two or more individual doses administered during the month.
- the monthly dose is administered in 2 or 3 weekly doses.
- the monthly dose is administered in 4 or 5 weekly doses.
- the monthly dose is administered in 28 to 31 daily doses.
- the monthly dose is administered in 5 to 10 individual doses during the month.
- the monthly dose may be administered for only 1 month, or may be repeatedly administered for 2 or more months.
- a six week dose of zoledronic acid may be about 200 mg to about 500 mg, about 300 mg to about 450 mg, or about 300 mg. In some embodiments, the six week dose of zoledronic acid may be administered only once. In some embodiments, the six week dose of zoledronic acid may be administered in six weekly doses, e.g about 35 mg to about 80 mg or about 50 mg to about 75 mg in each weekly dose.
- the oral zoledronic acid, or disodium salt thereof may be administered in combination with about 0.1 mg to about 10 mg of zoledronic acid, or a salt thereof, administered parenterally, such as intravenously.
- about 50 mg, about 100 mg, or about 150 mg of the disodium salt of zoledronic acid is administered orally in combination with 1 mg parenteral, such as intravenous, zoledronic acid.
- the parenteral dose of zoledronic acid is about 0.25 mg to about 25 mg, about 0.25 mg to about 10 mg, or about 0.5 mg to about 7.5 mg.
- zoledronic acid or another bisphosphonate
- the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage, (other than any water required to swallow the oral dosage form) for at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, or at least about 12 hours before the zoledronic acid is administered.
- the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, or at least about 4 hours after the zoledronic acid is administered.
- a human being to which the zoledronic acid is administered avoids lying down, or remains upright or sits upright, for at least about 30 minutes or about 1 hour after receiving a dosage form containing zoledronic acid. Avoiding food or beverage before or after oral administration of zoledronic acid can improve the bioavailability of the zoledronic acid.
- the oral bioavailability of zoledronic acid in a dosage form can vary. Some dosage forms may have ingredients added to enhance the bioavailability. However, bioavailability enhancement is not necessary for an oral dosage form to be effective. In some embodiments, the dosage form is substantially free of bioavailability-enhancing agents. In some embodiments, an oral dosage form may have an oral bioavailability of zoledronic acid of about 0.01 % to about 10%, about 0.1 % to about 7%, about 0.1 % to about 5%, etc. Without ingredients or other methods to enhance bioavailability, zoledronic acid typically has a low bioavailability in an oral dosage form.
- the oral bioavailability of zoledronic acid is unenhanced or substantially unenhanced.
- the oral bioavailability of zoledronic acid can be about 0.01 % to about 5%, about 1.1 % to about 4%, about 1.1 % to about 3.1 %, about 1.1 % to about 3.5%, about 1.5% to about 4%, about 1.5% to about 3.1 %, about 1.5% to about 3.5%, about 2% to about 3%, about 3% to about 4%, about 0.01 % to about 4%, about 0.1 % to about 3%, about 0.1 % to about 2%, about 0.2% to about 2%, about 0.2% to about 1.5%, about 0.3% to about 1.5%, about 0.3% to about 1 %, about 0.1 % to about 0.5%, about 0.3% to about 0.5%, about 0.5% to about 1 %, about 0.6% to about 0.7%, about 0.7% to about 0.8%, about 0.8% to about 0.9%, about 0.9%, about 1 .
- One embodiment is a pharmaceutical composition comprising zoledronic acid wherein the oral bioavailability of zoledronic acid in the dosage form is from about 0.01 % to about 10%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.01 % to about 5%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.1 % to about 7%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.1 % to about 5%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.1 % to about 3%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.1 % to about 2%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.2% to about 2%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.2% to about 1.5%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.3% to about 1.5%.
- the oral bioavailability of zoledronic acid in the dosage form is about 0.3% to about 1.0%.
- an oral dosage form comprises about 10 mg to about 300 mg of zoledronic acid, and is administered daily for about 2 to about 15 consecutive days. This regimen may be repeated once monthly, once every two months, once every three months, once every four months, once every five months, once every six months, once yearly, or once every two years.
- an oral dosage form comprises about 10 mg to about 150 mg or about 10 mg to about 100 mg of zoledronic acid, and is administered daily for about 2 to about 15 consecutive days. This regimen may be repeated once monthly, once every two months, once every three months, once every four months, once every five months, once every six months, once yearly, or once every two years.
- an oral dosage form comprises about 10 mg to about 150 mg or about 10 mg to about 100 mg of zoledronic acid, and is administered daily for about 5 to about 10 consecutive days. This regimen may be repeated once monthly, once every two months, once every three months, once every four months, once every five months, once every six months, once yearly, or once every two years.
- an oral dosage form comprises about 40 mg to about 150 mg of zoledronic acid, and is administered daily for about 5 to about 10 consecutive days. This regimen may be repeated once monthly, once every two months, once ever three months, once every four months, once every five months, once every six months, once yearly, or once every two years.
- the oral zoledronic acid may be administered as one dose of about 100 mg to about 2000 mg. In some embodiments, the oral zoledronic acid may be administered as one dose of about 300 mg to about 1500 mg. In some embodiments, the oral zoledronic acid may be administered as one dose of about 200 mg to about 1000 mg. The dose of zoledronic acid may be administered in a single or divided dose.
- Zoledronic acid may be formulated for oral administration, for example, with an inert diluent or with an edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly with the food of the diet.
- the active compound may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, coated tablets, troches, capsules, elixirs, dispersions, suspensions, solutions, syrups, wafers, patches, and the like.
- Tablets, troches, pills, capsules and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient, such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- an excipient such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin
- a flavoring agent such as peppermint
- a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. It may be desirable for material in a dosage form or pharmaceutical composition to be pharmaceutically pure and substantially non toxic in the amounts employed.
- compositions or dosage forms may be a liquid, or may comprise a solid phase dispersed in a liquid.
- Zoledronic acid may be formulated for parental or intraperitoneal administration.
- Solutions of the active compounds as free acids or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- a dispersion can also have an oil dispersed within, or dispersed in, glycerol, liquid polyethylene glycols, and mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- an oral dosage form may comprise a silicified microcrystalline cellulose such as Prosolv.
- a silicified microcrystalline cellulose such as Prosolv.
- about 20% (wt/wt) to about 70% (wt/wt), about 10% (wt/wt) to about 20% (wt/wt), about 20% (wt/wt) to about 40% (wt/wt), about 25% (wt/wt) to about 30% (wt/wt), about 40% (wt/wt) to about 50% (wt/wt), or about 45% (wt/wt) to about 50% (wt/wt) silicified microcrystalline cellulose may be present in an oral dosage form or a unit of an oral dosage form.
- an oral dosage form may comprise a crosslinked polyvinylpyrrolidone such as crospovidone.
- a crosslinked polyvinylpyrrolidone such as crospovidone.
- about 1 % (wt/wt) to about 10% (wt/wt), about 1 % (wt/wt) to about 5% (wt/wt), or about 1 % (wt/wt) to about 3% (wt/wt) crosslinked polyvinylpyrrolidone may be present in an oral dosage form or a unit of an oral dosage form.
- an oral dosage form may comprise a fumed silica such as Aerosil.
- a fumed silica such as Aerosil.
- about 0.1 % (wt/wt) to about 10% (wt/wt), about 0.1 % (wt/wt) to about 1 % (wt/wt), or about 0.4% (wt/wt) to about 0.6% (wt/wt) fumed silica may be present in an oral dosage form or a unit of an oral dosage form.
- an oral dosage form may comprise magnesium stearate.
- magnesium stearate For example, about 0.1 % (wt/wt) to about 10% (wt/wt), about 0.1 % (wt/wt) to about 1 % (wt/wt), or about 0.4% (wt/wt) to about 0.6% (wt/wt) magnesium stearate may be present in an oral dosage form or a unit of an oral dosage form.
- An oral dosage form comprising zoledronic acid or another bisphosphonate may be included in a pharmaceutical product comprising more than one unit of the oral dosage form.
- a pharmaceutical product containing oral dosage forms for daily use can contain 28, 29, 30, or 31 units of the oral dosage form for a monthly supply.
- An approximately 6 week daily supply can contain 40 to 45 units of the oral dosage form.
- An approximately 3 month daily supply can contain 85 to 95 units of the oral dosage form.
- An approximately six-month daily supply can contain 170 to 200 units of the oral dosage form.
- An approximately one year daily supply can contain 350 to 380 units of the oral dosage form.
- a pharmaceutical product containing oral dosage forms for weekly use can contain 4 or 5 units of the oral dosage form for a monthly supply.
- An approximately 2 month weekly supply can contain 8 or 9 units of the oral dosage form.
- An approximately 6 week weekly supply can contain about 6 units of the oral dosage form.
- An approximately 3 month weekly supply can contain 12, 13 or 14 units of the oral dosage form.
- An approximately six-month weekly supply can contain 22 to 30 units of the oral dosage form.
- An approximately one year weekly supply can contain 45 to 60 units of the oral dosage form.
- a pharmaceutical product may accommodate other dosing regimes.
- a pharmaceutical product may comprise 5 to 10 units of the oral dosage form, wherein each unit of the oral dosage form contains about 40 mg to about 150 mg of zoledronic acid.
- Some pharmaceutical products may comprise 1 to 10 units of the oral dosage form, wherein the product contains about 200 mg to about 2000 mg of zoledronic acid.
- each unit of the oral dosage form may be taken daily for 1 to 10 days or 5 to 10 days during a month, such as at the beginning of a month.
- Some oral dosage forms comprising zoledronic acid or a salt thereof may have enteric coatings or film coatings.
- zoledronic acid was administered in the disodium salt form as disodium zoledronate tetrahydrate. No bioavailability enhancing agents were used in the test compositions.
- CFA complete Freund's adjuvant
- Inflammatory pain was induced by injection of 100% CFA in a 75 ⁇ _ volume into the left hind paws of Sprague-Dawley rats on day 0, followed by assessments on days 1-3.
- Animals were orally administered vehicle (control), zoledronic acid 18 mg/m 2 (or 3 mg/kg), zoledronic acid 120 mg/m 2 (or 20 mg/kg), or zoledronic acid 900 mg/m 2 (or 150 mg/kg) daily on days 1-3.
- Drug was dissolved in distilled water and prepared fresh daily. Animals were fasted prior to dosing.
- Paw compression threshold was measured by applying increasing pressure to the plantar surface of the hind paw with a dome-shaped tip placed between the 3rd and 4th metatarsus. Pressure was applied gradually over approximately 10 seconds. Measurements were taken from the first observed nocifensive behavior of vocalization, struggle or withdrawal. A cut-off value of 300 g was used to prevent injury to the animal.
- % reversal ( Post-treatment - Post-CFA baseline)/(Pre-CFA baseline - Post-CFA baseline) x 100.
- Orally administered zoledronic acid produced a 29% reversal of inflammatory pain at the 18 mg/m 2 , and a 48% reversal at the 900 mg/m 2 dose. This magnitude of effect is comparable to that obtained with clinical doses of commercially available NSAIDs when tested in a similar model of inflammatory pain.
- the reference body surface area of a human adult is 1.62 m 2 .
- a daily dose of 18 mg/m 2 corresponds to a monthly dose of about 500-560 mg/m 2 or a human dose of about 800-900 mg.
- CFA complete Freund's adjuvant
- injection of 100% complete Freund's adjuvant (CFA) in a 75 ⁇ _ volume into the left hind paws is followed by a 10-14 day period to allow for the development of arthritis pain.
- Animals were orally administered vehicle (control), zoledronic acid 54 mg/m 2 (or 9 mg/kg), or zoledronic acid 360 mg/m 2 (or 60 mg/kg), divided in three equal daily doses on the first three days post CFA injection. Drug was dissolved in distilled water and prepared fresh daily. Animals were fasted prior to dosing.
- % reversal (ipsilateral drug threshold - ipsilateral vehicle threshold)/(contralateral vehicle threshold - ipsilateral vehicle threshold) x 100.
- Oral administration of zoledronic acid significantly improved arthritis pain thresholds compared to vehicle.
- orally administered zoledronic acid produced a dose-dependent reversal of arthritis pain.
- a reversal of 33% was observed in the 54 mg/m 2 group, and reversal of 54% was observed in the 360 mg/m 2 group.
- the reference body surface area of a human adult is 1.62 m 2 .
- 54 mg/m 2 in a rat is equivalent to an implied human dose of about 87 mg
- 360 mg/m 2 in a rat is equivalent to an implied human dose of about 583 mg.
- CRPS complex regional pain syndrome
- An incapacitance device (IITC Inc. Life Science, Woodland, CA, USA) was used to measure hindpaw weight bearing, a postural effect of pain.
- the rats were manually held in a vertical position over the apparatus with the hindpaws resting on separate metal scale plates and the entire weight of the rat was supported on the hindpaws. The duration of each measurement was 6 seconds and 10 consecutive measurements were taken at 60-second intervals. Eight readings (excluding the highest and lowest ones) were averaged to calculate the bilateral hindpaw weight- bearing values. Weight bearing data were analyzed as the ratio between right (fracture) and left hindpaw weight bearing values ((2R/(R+L)) *100%).
- a laser sensor technique was used to determine the dorsal-ventral thickness of the hindpaw.
- the bilateral hindpaws were tattooed with a 2 to 3 mm spot on the dorsal skin over the midpoint of the third metatarsal.
- each rat was briefly anesthetized with isoflurane and then held vertically so the hindpaw rested on a table top below the laser.
- the paw was gently held flat on the table with a small metal rod applied to the top of the ankle joint.
- a laser with a distance measuring sensor was used to determine the distance to the table top and to the top of the hindpaw at the tattoo site and the difference was used to calculate the dorsal-ventral paw thickness.
- the measurement sensor device used in these experiments (4381 Precicura, Limab, Goteborg, Sweden) has a measurement range of 200 mm with a 0.01 mm resolution.
- the temperature of the hindpaw was measured using a fine wire thermocouple (Omega, Stanford, CT, USA) applied to the paw skin. Six sites were tested per hindpaw. The six measurements for each hindpaw were averaged for the mean temperature.
- Zoledronic acid reduced hindpaw warmth by 5% versus vehicle treatment.
- the daily dose in the above experiment was 18 mg/m 2 /day. Under current FDA guidelines, the reference body surface area of a human adult is 1.62 m 2 . Thus, a daily dose of 18 mg/m 2 corresponds to a monthly dose of about 500-560 mg/m 2 or a human dose of about 800-900 mg.
- Example 6 Solubility of Disodium Salt of Zoledronic Acid
- the aqueous solubility of zoledronic acid and disodium zoledronate tetrahydrate was determined.
- One gram of the test compound was measured in to a beaker.
- Demineralized water (pH 5.5) was then added in small increments to the test compound, and sonification was applied to the mixture. The procedure was continued until complete dissolution was achieved. Full dissolution was determined to have been reached when a clear solution was present with no visible material. The volume of water required to reach full dissolution was used to calculate a solubility value expressed in grams per 100 imL The procedure was performed for each compound.
- the aqueous solubility of disodium zoledronate tetrahydrate is approximately 50 times that of zoledronic acid.
- Disodium zoledronate tetrahydrate has a solubility of 12.5 g/100 ml_ compared to only 0.25 g/100 ml_ for zoledronic acid.
- Tablets were manufactured containing either pure zoledronic acid or the disodium salt of zoledronic acid (disodium zoledronate tetrahydrate). Both types of tablets contained 50 mg of zoledronic acid equivalent per tablet. Identical excipients were used in both types of tablets, with amounts adjusted to account for the difference in molecular weights between the acid and the disodium salt.
- Beagle dogs were orally administered tablets containing 150 mg zoledronic acid equivalent either in the form of disodium zoledronate (Group 1 ) or pure zoledronic acid (Group 2). Each animal was given three 50 mg equivalent tablets (150 mg total), which were administered together. The animal's oral cavity was wetted with water before placing the tablets on the back of the animal's tongue. Animals were fasted before and after dosing. Animals were 6 to 9 months of age and weighed 6 to 10 kg on the day of dosing. There were three dogs per group.
- Disodium zoledronate produced significantly higher plasma levels zoledronic acid than pure zoledronic acid, indicating improved oral absorption with the salt form.
- C max peak plasma concentrations
- the disodium salt resulted in a 1 19% actual and 74% weight- adjusted increase in bioavailability as compared to pure zoledronic acid.
- AUCo-inf area under the plasma concentration curve
- the average AUC 0 - ⁇ for the disodium salt was 4073 ng « hr/ml_ and the average AUC 0 - ⁇ for the diacid was 2217 ng « hr/ml_.
- the AUC 0 -inf was found to be dose proportional.
- about 3 mg to about 4 mg of the disodium salt would be expected to result in an AUCo- ⁇ of about 100 ng « hr/ml_, and about 7 mg to about 8 mg of the disodium salt would be expected to result in an AUC 0 - ⁇ of about 200 ng « hr/ml_.
- Tablets were prepared by blending zoledronic acid, either in the form of the free acid or the disodium salt, with identical excipients. For dosage forms with a greater amount of active, the amount of the excipients was reduced proportionally to keep the weight of the tablet at about 100 mg. After blending, the ingredients were compressed at varying pressures, followed by a film coating. The resulting tablets were then tested for hardness using a Dr. Schleuniger Pharmatron 8M Tablet Hardness Tester. The results are shown in Table 2 and FIG. 9.
- Embodiment 1 A method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the mammal receives a total monthly dose of zoledronic acid that is about 800 mg/m 2 or less based upon the body surface area of the mammal.
- Embodiment 2 The method of embodiment 1 , wherein the mammal is a human being that receives a total monthly dose of zoledronic acid that is about 30 mg/m 2 to about 700 mg/m 2 .
- Embodiment 3 The method of embodiment 2, wherein the total monthly dose is administered in 4 or 5 weekly doses.
- Embodiment 4 The method of embodiment 2, wherein the total monthly dose is administered in 28 to 31 daily doses.
- Embodiment 5 The method of embodiment 2, wherein the total monthly dose is administered in 5 to 10 individual doses during the month.
- Embodiment 6 The method of embodiment 1 , wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 300 mg.
- Embodiment 7 The method of embodiment 6, wherein the total weekly dose is a single dose, administered once a week.
- Embodiment 8 The method of embodiment 6, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.
- Embodiment 9 The method of embodiment 1 , wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 150 mg.
- Embodiment 10 The method of any preceding embodiment, wherein the mammal experiences significant pain relief more than 3 hours after administration of the dosage form.
- Embodiment 11 The method of embodiment 10, wherein the mammal experiences significant pain relief during at least a part of a time from about 3 hours to about 24 hours after administration of the dosage form.
- Embodiment 12 The method of embodiment 10, wherein the mammal experiences significant pain relief during at least a part of a time from about 3 hours to about 3 weeks after administration of the dosage form.
- Embodiment 13 A method of relieving inflammatory pain comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof, wherein the oral dosage form contains about 10 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the mammal.
- Embodiment 14 The method of embodiment 13, wherein the oral dosage form contains about 15 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the mammal.
- Embodiment 15 A method of relieving inflammatory pain comprising orally administering to a mammal in need thereof, about 300 mg/m 2 to about 600 mg/m 2 of zoledronic acid per month to the mammal, based upon the body surface area of the mammal.
- Embodiment 16 The method of embodiment 15, comprising orally administering about 450 mg/m 2 to about 600 mg/m 2 of zoledronic acid per month to the mammal, based upon the body surface area of the mammal.
- Embodiment 17 The method of any preceding embodiment, wherein the mammal is not suffering from bone metastasis.
- Embodiment 18 The method of any preceding embodiment, wherein the mammal is not suffering from cancer.
- Embodiment 19 The method of any preceding embodiment, wherein the zoledronic acid is administered as a salt of a dianion of zoledronic acid.
- Embodiment 20 A method of relieving pain associated with an arthritis comprising administering an oral dosage form containing zoledronic acid to a human being in need thereof.
- Embodiment 21 The method of embodiment 20, wherein the human being receives a total monthly dose of zoledronic acid that is about 40 mg to about 2000 mg.
- Embodiment 22 The method of embodiment 21 , wherein the total monthly dose is administered in 4 or 5 weekly doses.
- Embodiment 23 The method of embodiment 21 , wherein the total monthly dose is administered in 28 to 31 daily doses.
- Embodiment 24 The method of embodiment 21 , wherein the total monthly dose is administered in 5 to 10 individual doses during the month.
- Embodiment 25 The method of embodiment 20, wherein the human being receives a total weekly dose of zoledronic acid that is about 100 mg to about 300 mg.
- Embodiment 26 The method of embodiment 25, wherein the total weekly dose is a single dose, administered once a week.
- Embodiment 27 The method of embodiment 25, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.
- Embodiment 28 The method of embodiment 20, wherein the human being receives a total weekly dose of zoledronic acid that is about 10 mg to about 100 mg.
- Embodiment 29 The method of any of embodiments 20-28, wherein the human being experiences significant pain relief more than 3 hours after administration of the dosage form.
- Embodiment 30 The method of embodiment 29, wherein the human being experiences significant pain relief during at least a part of a time from about 3 hours to about 24 hours after administration of the dosage form.
- Embodiment 31 The method of embodiment 29, wherein the human being experiences significant pain relief during at least a part of a time from about 3 hours to about 3 weeks after administration of the dosage form.
- Embodiment 32 The method of any of embodiments 20-31 , wherein the dosage form contains about 10 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the human being.
- Embodiment 33 The method of embodiment 32, wherein the dosage form contains about 15 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the human being.
- Embodiment 34 The method of any of embodiments 20-33, wherein about 50 mg/m 2 to about 200 mg/m 2 of zoledronic acid is orally administered per month, based upon the body surface area of the human being.
- Embodiment 35 The method of any of embodiments 20-31 , wherein the dosage form contains about 80 mg/m 2 to about 150 mg/m 2 of zoledronic acid based upon the body surface area of the human being.
- Embodiment 36 The method of embodiment 35, wherein about 300 mg/m 2 to about 1000 mg/m 2 of zoledronic acid is orally administered per month, based upon the body surface area of the human being.
- Embodiment 37 The method of any of embodiments 20-36, wherein the human being is not suffering from bone metastasis.
- Embodiment 38 The method of any of embodiments 20-37, wherein the human being is not suffering from cancer.
- Embodiment 39 The method of any preceding embodiment, wherein the zoledronic acid is in the disodium salt form.
- Embodiment 40 An oral dosage form comprising zoiedronic acid, wherein the oral bioavailability of zoledronic acid in the dosage form is about 0.01 % to about 4%.
- Embodiment 41 The oral dosage form of embodiment 40, wherein the oral dosage form contains about 10 mg to about 300 mg of zoiedronic acid.
- Embodiment 42 The oral dosage form of embodiment 40, wherein the oral dosage form contains about 10 mg to about 50 mg of zoiedronic acid.
- Embodiment 43 The oral dosage form of any of embodiments 40-42, wherein the oral bioavailability of zoledronic acid in the dosage form is about 0.1 % to about 2%.
- Embodiment 44 A pharmaceutical product comprising more than one unit of an oral dosage form of embodiment 40.
- Embodiment 45 The pharmaceutical product of embodiment 44, wherein each unit of the oral dosage form contains about 1 mg to about 50 mg of zoledronic acid.
- Embodiment 46 The pharmaceutical product of embodiment 45, comprising 28, 29, 30, or 31 units of the oral dosage form, for a total of about 28 mg to about 1600 mg of zoiedronic acid to be administered in about 1 month.
- Embodiment 47 The pharmaceutical product of embodiment 45, comprising 85 to 95 units of the oral dosage form, for a total of about 85 mg to about 4800 mg of zoledronic acid to be administered in about 3 months.
- Embodiment 48 The pharmaceutical product of embodiment 45, comprising 170 to 200 units of the oral dosage form, for a total of about 170 mg to about 10,000 mg of zoiedronic acid to be administered in about 6 months.
- Embodiment 49 The pharmaceutical product of embodiment 45, comprising 350 to 380 units of the oral dosage form, for a total of about 350 mg to about 19,000 mg of zoledronic acid to be administered in about 1 year.
- Embodiment 50 The pharmaceutical product of embodiment 44, wherein each unit of the oral dosage form contains about 10 mg to about 300 mg.
- Em odiment 51 The pharmaceutical product of embodiment 50, comprising 4 or 5 units of the oral dosage form, for a total of about 40 mg to about 1500 mg of zoledronic acid to be administered within a period of about 1 month.
- Embodiment 52 The pharmaceutical product of embodiment 50, comprising 8 or 9 units of the oral dosage form, for a total of about 80 mg to about 2700 mg of zoledronic acid to be administered in about 2 months.
- Embodiment 53 The pharmaceutical product of embodiment 50, comprising 12, 13 or 14 units of the oral dosage form, for a total of about 120 mg to about 4200 mg of zoledronic acid to be administered in about 3 months.
- Embodiment 54 The pharmaceutical product of embodiment 50, comprising 22 to 30 units of the oral dosage form, for a total of about 220 mg to about 9000 mg of zoledronic acid to be administered in about 6 months.
- Embodiment 55 The pharmaceutical product of embodiment 50, comprising 45 to 60 units of the oral dosage form, for a total of about 450 mg to about 18000 mg of zoledronic acid to be administered in about 1 year.
- Embodiment 56 The pharmaceutical product of embodiment 44, comprising 1 to 10 units of the oral dosage form, wherein the product contains about 200 mg to about 2000 mg of zoledronic acid.
- Embodiment 57 The oral dosage form of any preceding embodiment, wherein the zoledronic acid is in the form of a sodium salt.
- Embodiment 58 The oral dosage form of any preceding embodiment, wherein the zoledronic acid is in a form that has an aqueous solubility greater than 1 % (w/v).
- Embodiment 59 The oral dosage form of any preceding embodiment, wherein the zoledronic acid is in a form that has an aqueous solubility of about 5% (w/v) to about 50% (w/v).
- Embodiment 60 An oral dosage form comprising zoledronic acid and an excipient, wherein the zoledronic acid is in a form that has an aqueous solubility greater than 1 % (w/v).
- Embodiment 61 The oral dosage form of embodiment 60, wherein the zoledronic acid is in a form that has an aqueus solubility of about 5% (w/v) to about 50% (w/v).
- Embodiment 62 A method of treating complex regional pain syndrome comprising administering an oral dosage form containing zoledronic acid to a mammal in need thereof.
- Embodiment 63 The method of embodiment 62, wherein the mammal is a human being that receives an amount of zoledronic acid that is about 30 mg/m 2 to about 700 mg/m 2 in a period of one month or less.
- Embodiment 64 The method of embodiment 63, wherein 4 or 5 weekly doses are administered in a period of one month or less.
- Embodiment 65 The method of embodiment 63, wherein 28 to 31 daily doses are administered in a period of one month or less.
- Embodiment 66 The method of embodiment 63, wherein 5 to 10 individual doses are administered during a period of one month or less.
- Embodiment 67 The method of embodiment 63, wherein about 30 mg/m 2 to about 700 mg/m 2 of zoledronic acid is administered during only one month.
- Embodiment 68 The method of embodiment 63, wherein about 30 mg/m 2 to about 700 mg/m 2 of zoledronic acid is administered in a period of one month or less for 2 or more consecutive months.
- Embodiment 69 The method of embodiment 62, wherein the mammal receives about 10 mg/m 2 to about 30 mg/m 2 of zoledronic acid daily.
- Embodiment 70 The method of embodiment 62, wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is about 10 mg to about 300 mg.
- Embodiment 71 The method of embodiment 70, wherein the total weekly dose is a single dose, administered once a week.
- Embodiment 72 The method of embodiment 70, wherein the total weekly dose is administered in 2 to 7 individual doses during the week.
- Embodiment 73 The method of any of embodiments 62-72, wherein the complex regional pain syndrome is complex regional pain syndrome type I.
- Embodiment 74 The method of any of embodiments 62-72, wherein the complex regional pain syndrome is complex regional pain syndrome type II.
- Embodiment 75 The method of any preceding embodiment, wherein the zoledronic acid is in a salt form.
- Embodiment 76 The method of any of embodiments 62-75, wherein the dosage form contains about 10 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the mammal.
- Embodiment 77 The method of embodiment 76, wherein the dosage form contains about 15 mg/m 2 to about 20 mg/m 2 of zoledronic acid based upon the body surface area of the mammal.
- Embodiment 78 A method of treating complex regional pain syndrome, comprising administering pamidronic acid to a human being in need thereof.
- Embodiment 79. A method of treating complex regional pain syndrome, comprising administering neridronic acid to a human being in need thereof.
- Embodiment 80 A method of treating complex regional pain syndrome, comprising administering olpadronic acid to a human being in need thereof.
- Embodiment 81 A method of treating complex regional pain syndrome, comprising administering alendronic acid to a human being in need thereof.
- Embodiment 82 A method of treating complex regional pain syndrome, comprising administering incadronic acid to a human being in need thereof.
- Embodiment 83 A method of treating complex regional pain syndrome, comprising administering ibandronic acid to a human being in need thereof.
- Embodiment 84 A method of treating complex regional pain syndrome, comprising administering risedronic acid to a human being in need thereof.
- Embodiment 85 A method of treating pain, comprising administering pamidronic acid to a human being in need thereof.
- Embodiment 86 A method of treating pain, comprising administering neridronic acid to a human being in need thereof.
- Embodiment 87 A method of treating pain, comprising administering olpadronic acid to a human being in need thereof.
- Embodiment 88 A method of treating pain, comprising administering alendronic acid to a human being in need thereof.
- Embodiment 89 A method of treating pain, comprising administering incadronic acid to a human being in need thereof.
- Embodiment 90 A method of treating pain, comprising administering ibandronic acid to a human being in need thereof.
- Embodiment 91 A method of treating pain, comprising administering risedronic acid to a human being in need thereof.
- Embodiment 92 A method of treating arthritis pain, comprising administering pamidronic acid to a human being in need thereof.
- Embodiment 93 A method of treating arthritis pain, comprising administering neridronic acid to a human being in need thereof.
- Embodiment 94 A method of treating arthritis pain, comprising administering olpadronic acid to a human being in need thereof.
- Embodiment 95 A method of treating arthritis pain, comprising administering alendronic acid to a human being in need thereof.
- Embodiment 96 A method of treating arthritis pain, comprising administering incadronic acid to a human being in need thereof.
- Embodiment 97 A method of treating arthritis pain, comprising administering ibandronic acid to a human being in need thereof.
- Embodiment 98 A method of treating arthritis pain, comprising administering risedronic acid to a human being in need thereof.
- Embodiment 99 A method of treating inflammatory pain, comprising administering pamidronic acid to a human being in need thereof.
- Embodiment 100 A method of treating inflammatory pain, comprising administering neridronic acid to a human being in need thereof.
- Embodiment 101 A method of treating inflammatory pain, comprising administering olpadronic acid to a human being in need thereof.
- Embodiment 102 A method of treating inflammatory pain, comprising administering alendronic acid to a human being in need thereof.
- Embodiment 103 A method of treating inflammatory pain, comprising administering incadronic acid to a human being in need thereof.
- Embodiment 104 A method of treating inflammatory pain, comprising administering ibandronic acid to a human being in need thereof.
- Embodiment 105 A method of treating inflammatory pain, comprising administering risedronic acid to a human being in need thereof.
- Embodiment 106 A method of treating complex regional pain syndrome, comprising administering etidronic acid to a human being in need thereof.
- Embodiment 107 A method of treating pain, comprising administering etidronic acid to a human being in need thereof.
- Embodiment 108 A method of treating arthritis pain, comprising administering etidronic acid to a human being in need thereof.
- Embodiment 109 A method of treating inflammatory pain, comprising administering etidronic acid to a human being in need thereof.
- Embodiment 110 A method of treating complex regional pain syndrome, comprising administering clodronic acid to a human being in need thereof.
- Embodiment 111 A method of treating pain, comprising administering clodronic acid to a human being in need thereof.
- Embodiment 112. A method of treating arthritis pain, comprising administering clodronic acid to a human being in need thereof.
- Embodiment 113 A method of treating inflammatory pain, comprising administering clodronic acid to a human being in need thereof.
- Embodiment 114 A method of treating complex regional pain syndrome, comprising administering tiludronic acid to a human being in need thereof.
- Embodiment 115 A method of treating pain, comprising administering tiludronic acid to a human being in need thereof.
- Embodiment 116 A method of treating arthritis pain, comprising administering tiludronic acid to a human being in need thereof.
- Embodiment 117 A method of treating inflammatory pain, comprising administering tiludronic acid to a human being in need thereof.
- Embodiment 118 The method of any of embodiments 78-1 17, wherein the active compound is orally administered.
- Embodiment 119 The method of any of embodiments 78-1 17, wherein the active compound is parenterally administered.
- Embodiment 120 A method of enhancing the oral bioavailability of zoledronic acid comprising orally administering a dosage form containing zoledronic acid in the disodium salt form.
- Embodiment 121 The method of embodiment 120, wherein the zoledronic acid in the disodium salt form provides an enhancement to bioavailability, as compared to zoledronic acid in the diacid form, which adds to any enhancement to bioavailability provided by any bioavailability-enhancing agents in the dosage form.
- Embodiment 122 The method of embodiment 120, wherein the dosage form is substantially free of bioavailability-enhancing agents.
- Embodiment 123 The method of embodiment 120, wherein the zoledronic acid in the disodium salt form is administered to a mammal in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 2000 ng « h/ml_ to the mammal each time the zoledronic acid in the disodium salt is administered.
- Embodiment 124 The method of embodiment 120, wherein the zoledronic acid in the disodium salt form is administered to a mammal in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 2000 ng « h/ml_ to the mammal each time the zoledronic acid in the disodium salt is administered.
- Embodiment 125 The method of embodiment 123, wherein the zoledronic acid in the disodium salt form is administered weekly, or 3 to 5 times in a month, in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 20 ng « h/ml_ to about 700 ng « h/ml_ to the mammal each time the zoledronic acid in the disodium salt form is administered.
- Embodiment 126 The method of embodiment 123, wherein the zoledronic acid in the disodium salt form is administered daily in an amount that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 100 ng « h/ml_ to the mammal each time the zoledronic acid in the disodium salt form is administered.
- Embodiment 127 The method of embodiment 120, wherein the dosage form is a solid.
- Embodiment 128 The method of embodiment 120, 121 , 122, 123, 124, 125, 126, or 127, wherein the bioavailability of zoledronic acid is improved by at least about 20% as compared to administration of zoledronic acid in the diacid form.
- Embodiment 129 The method of embodiment 120, 121 , 122, 123, 124, 125, 126, 127, or 128, further comprising administering, on a molar basis, less of the zoledronic acid in the disodium salt form than would be administered of zoledronic acid in the diacid form in order to achieve the same plasma levels of zoledronic acid.
- Embodiment 130 The method of embodiment 129, wherein at least about 10 mole% less of the disodium salt form is administered as compared the amount of zoledronic acid in the diacid form that would be administered in order to achieve the same plasma levels of zoledronic acid.
- Embodiment 131 The method of embodiment 129, wherein the disodium salt form is administered in an amount, on a molar basis, that has a value of about 0.8n d to about 1.2n d , wherein:
- n a is the number of moles of zoledronic acid in the diacid form that would be administered in order to achieve the same plasma levels of zoledronic acid.
- Embodiment 132 The method of embodiment 131 , wherein the disodium salt is administered in an amount that has a value of about n d .
- Embodiment 133 The method of any of embodiments 120-132, wherein the zoledronic acid is used to treat an inflammatory condition.
- Embodiment 134 The method of embodiment 133, wherein the zoledronic acid is used to treat arthritis.
- Embodiment 135. The method of embodiment 133, wherein the zoledronic acid is used to treat complex regional pain syndrome.
- Embodiment 136 The method of any of embodiments 1-39, 62-77, and 120-135, wherein:
- a first oral dosage form is administered
- a second oral dosage form is administered
- the second oral dosage form is administered at 10 x T max or greater, wherein T max is the time of maximum plasma concentration for the first oral dosage form.
- Embodiment 137 A dosage form comprising zoledronic acid in the disodium salt form, wherein the bioavailability, in a mammal, of zoledronic acid in the disodium salt form is greater than the bioavailability of zoledronic acid in the diacid form would be in the same dosage form.
- Embodiment 138 A dosage form comprising zoledronic acid in the disodium salt form, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 2000 ng « h/ml_ to a human being to which the dosage form is administered.
- Embodiment 139 The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 100 ng « h/ml_ to about 2000 ng « h/ml_ to a human being to which the dosage form is administered.
- Embodiment 140 The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 20 ng « h/ml_ to about 700 ng « h/ml_ to a human being to which the dosage form is administered.
- Embodiment 141 The dosage form of embodiment 138, wherein the dosage form contains an amount of zoledronic acid in the disodium salt form that provides an area under the plasma concentration curve of zoledronic acid of about 4 ng « h/ml_ to about 100 ng « h/ml_ to a human being to which the dosage form is administered.
- Embodiment 142 A dosage form comprising zoledronic acid in the disodium salt form,
- disodium salt form is present in a lower molar amount than would be present if the zoledronic acid were in the diacid form
- the zoledronic acid in the disodium salt form has an improved bioavailability as compared to the zoledronic acid in the diacid form to the extent that the lower molar amount of the disodium salt in the dosage form does not reduce the amount of zoledronic acid delivered to the plasma of a mammal.
- Embodiment 143 The dosage form of embodiment 137, 138, 139, 140, 141 , or 142, wherein the dosage form is a solid.
- Embodiment 144 The dosage form of embodiment 142 or 143, wherein the bioavailability of zoledronic acid in the disodium salt form is improved by at least about 10% as compared to an otherwise identical dosage form containing zoledronic acid in the diacid form.
- Embodiment 145 The dosage form of embodiment 142, 143, or 144, containing at least about 20 mole% less of the disodium salt form as compared to the amount of the zoledronic acid in the diacid form that would be present if the zoledronic acid were in the diacid form.
- Embodiment 146 The dosage form of embodiment 142, wherein the disodium salt form is present in an amount, on a molar basis, that has a value of about 0.9nd to about 1.1 nd, wherein:
- b a is the bioavailability of the diacid form
- b d is the bioavailability of the disodium salt form
- n a is the number of moles of the diacid form that would be present if the zoledronic acid were in the diacid form.
- Embodiment 147 The dosage form of embodiment 146, wherein the disodium salt is administered in an amount that has a value of about n d .
- Embodiment 148 The method of any of embodiments 1-39, 62-77, and 120-136, wherein:
- a first oral dosage form is administered, and a second oral dosage form is administered after the first oral dosage form, wherein the second oral dosage form is administered before the maximum pain relieving effect of the first oral dosage form is achieved, or the second oral dosage form is administered before an observable pain relieving effect is achieved.
- Embodiment 149 The method of embodiment 148, wherein the second oral dosage form is administered before an observable pain relieving effect is achieved.
- Embodiment 150 The method of any of embodiments 1-39, 62-77, and 120-132, wherein a first dosage form is administered, followed by administration of a second dosage form, wherein the second dosage form is administered after the maximum pain relieving effect of the first oral dosage form is achieved, and the second oral dosage form is administered while a pain relieving effect from the first oral dosage form is observable.
- Embodiment 151 The method of embodiment 148, 149, or 150, wherein the second oral dosage form is administered about 24 hours to about 28 days after the first oral dosage form is administered.
- Embodiment 152 The method of any of embodiments 20-39, wherein the human being is about 30 years old to about 75 years old.
- Embodiment 153 The method of any of embodiments 20-39, wherein the human being is about 1 year old to about 16 years old.
- Embodiment 154 The method of any of embodiments 20-39, wherein the human being is about 80 years old to about 95 years old.
- Embodiment 155 The method of any of embodiments 20-39, wherein the human being has suffered from the arthritis for at least 2 months.
- Embodiment 156 The method of any of embodiments 20-39, wherein the arthritis affects, a knee, an elbow, a finger, a wrist, a shoulder, or a hip.
- Embodiment 157 The method of any of embodiments 1-44, 62-133, and 144- 156, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour before the zoledronic acid is administered.
- Embodiment 158 The method of embodiment 157, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours before the zoledronic acid is administered.
- Embodiment 159 The method of embodiment 158, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 4 hours before the zoledronic acid is administered.
- Embodiment 160 The method of embodiment 159, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 6 hours before the zoledronic acid is administered.
- Embodiment 161 The method of any of embodiments 157-160, wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered.
- Embodiment 162 The method of embodiment 161 , wherein the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 1 hour after the zoledronic acid is administered.
- Embodiment 163 The method of embodiment 161 , where in the mammal or human being to which the zoledronic acid is administered does not eat food or drink beverage for at least 2 hours after the zoledronic acid is administered.
- Embodiment 164 The method, dosage form, or product, of any preceding embodiment, wherein the zoledronic acid in the oral dosage form has a 24 hour sustained plasma level factor of about 1 or higher.
- Embodiment 165 The method, dosage form, or product, of any preceding embodiment, wherein the zoledronic acid in the oral dosage form has a 24 hour sustained plasma level factor that is higher than that of intravenously administered zoledronic acid.
- Embodiment 166 The method, dosage form, or product, of any preceding embodiment, wherein the oral dosage form is a solid that has a hardness of about 5 kPa to about 20 kPa.
- Embodiment 167 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 50 ng hr/mL to about 700 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 168 Embodiment 168.
- zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 130 ng hr/mL to about 180 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 169 The method, dosage form, or product of embodiment 167, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 300 ng hr/mL to about 450 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 170 The method, dosage form, or product of embodiment 167, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 300 ng hr/mL to about 350 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 171 The method, dosage form, or product of embodiment 167, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 370 ng hr/mL to about 420 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 172 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 300 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 173 The method, dosage form, or product of embodiment 172, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 50 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 174 The method, dosage form, or product of embodiment 172, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 50 ng/mL to about 200 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 175. The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.4 hr to about 1 hr.
- Embodiment 176. The method, dosage form, or product of embodiment 175, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.5 hr.
- Embodiment 177 The method, dosage form, or product of embodiment 175, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.75 hr.
- Embodiment 178 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 12 to about 50 for the particular species of mammal.
- Embodiment 179 The method, dosage form, or product of embodiment 178, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 20 to about 40 for the particular species of mammal.
- Embodiment 180 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 30 for the particular species of mammal.
- Embodiment 181 The method, dosage form, or product of embodiment 180, wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 20 for the particular species of mammal.
- Embodiment 182 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 6 to about 20 for the particular species of mammal.
- Embodiment 183 The method, dosage form, or product of embodiment 182, wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 8 to about 15 for the particular species of mammal.
- Embodiment 184 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 5 to about 20 for the particular species of mammal.
- Embodiment 185 The method, dosage form, or product of embodiment 184, wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 6 to about 15 for the particular species of mammal.
- Embodiment 186 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 4 to about 20 for the particular species of mammal.
- Embodiment 187 The method, dosage form, or product of embodiment 186, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 5 to about 10 for the particular species of mammal.
- Embodiment 188 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 12 hours that is about 0.5 ng/mL to about 5 ng/mL.
- Embodiment 189 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 24 hours that is about 0.2 ng/mL to about 2 ng/mL.
- Embodiment 190 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 36 hours that is about 0.1 ng/mL to about 2 ng/mL.
- Embodiment 191 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 48 hours that is about 0.1 ng/mL to about 2 ng/mL.
- Embodiment 192 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 72 hours that is about 0.2 ng/mL to about 1 ng/mL.
- the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 30 hours to about 100 hours.
- Embodiment 194 The method, dosage form, or product of any preceding embodiment, wherein the oral dosage form comprising zoledronic acid has a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 40 hours to about 60 hours.
- Embodiment 195 An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in an area under the plasma concentration curve (AUC) of zoledronic acid of about 50 ng hr/mL to about 700 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- AUC area under the plasma concentration curve
- Embodiment 196 The oral dosage form of embodiment 195, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 130 ng hr/mL to about 180 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 197 The oral dosage form of embodiment 195, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 300 ng hr/mL to about 450 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 198 The oral dosage form of embodiment 195, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 300 ng hr/mL to about 350 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 199 The oral dosage form of embodiment 195, wherein the zoledronic acid is present in an amount that results in an AUC of zoledronic acid of about 370 ng hr/mL to about 420 ng hr/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 200 An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 300 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 201 The oral dosage form of embodiment 200, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 5 ng/mL to about 50 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 202 The oral dosage form of embodiment 200, wherein the zoledronic acid is present in an amount that results in a C max of zoledronic acid of about 50 ng/mL to about 200 ng/mL upon administration of the oral dosage form to the particular species of mammal.
- Embodiment 203 An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.4 hr to about 1 hr.
- Embodiment 204 The oral dosage form of embodiment 203, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.5 hr.
- Embodiment 205 The oral dosage form of embodiment 203, wherein the oral dosage form is configured so that administration of the oral dosage form to the particular species of mammal results in a T max of zoledronic acid of about 0.75 hr.
- Embodiment 206 An oral dosage form comprising zoledronic acid having a dose of zoledronic acid and a configuration suitable for a particular species of mammal, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 12 to about 50 for the particular species of mammal.
- Embodiment 207 The oral dosage form of embodiment 206, wherein the oral dosage form is configured so that the zoledronic acid has a 12 hour sustained plasma level factor of about 20 to about 40 for the particular species of mammal.
- Embodiment 208 The oral dosage form of embodiment 206 or 207 wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 30 for the particular species of mammal.
- Embodiment 209 The oral dosage form of any of embodiments 206-208, wherein the oral dosage form is configured so that the zoledronic acid has a 24 hour sustained plasma level factor of about 10 to about 20 for the particular species of mammal.
- Embodiment 210 The oral dosage form of any of embodiments 206-209 wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 6 to about 20 for the particular species of mammal.
- Embodiment 211 The oral dosage form of any of embodiments 206-210, wherein the oral dosage form is configured so that the zoledronic acid has a 36 hour sustained plasma level factor of about 8 to about 15 for the particular species of mammal.
- Embodiment 212 The oral dosage form of any of embodiments 206-21 1 , wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 5 to about 20 for the particular species of mammal.
- Embodiment 213 The oral dosage form of any of embodiments 206-212, wherein the oral dosage form is configured so that the zoledronic acid has a 48 hour sustained plasma level factor of about 6 to about 15 for the particular species of mammal.
- Embodiment 214 The oral dosage form of any of embodiments 206-213, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 4 to about 20 for the particular species of mammal.
- Embodiment 215. The oral dosage form of any of embodiments 206-213, wherein the oral dosage form is configured so that the zoledronic acid has a 72 hour sustained plasma level factor of about 5 to about 10 for the particular species of mammal.
- Embodiment 216 The oral dosage form of any of embodiments 206-215, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 12 hours that is about 0.5 ng/mL to about 5 ng/mL.
- Embodiment 217 The oral dosage form of any of embodiments 206-216, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 24 hours that is about 0.2 ng/mL to about 2 ng/mL.
- Embodiment 218 The oral dosage form of any of embodiments 206-217, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 36 hours that is about 0.1 ng/mL to about 2 ng/mL.
- Embodiment 219. The oral dosage form of any of embodiments 206-218, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 48 hours that is about 0.1 ng/mL to about 2 ng/mL.
- Embodiment 220 The oral dosage form of any of embodiments 206-219, wherein the oral dosage form is configured so that the particular species of mammal has a plasma concentration of zoledronic acid at 72 hours that is about 0.2 ng/mL to about 1 ng/mL.
- Embodiment 221 The oral dosage form of any of embodiments 206-220, wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 30 hours to about 100 hours.
- Embodiment 222 The oral dosage form of any of embodiments 206-221 , wherein the oral dosage form is configured so that the elimination half-life of zoledronic acid in the particular species of mammal is about 40 hours to about 60 hours.
- all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood in all instances as indicating both the exact values as shown and as being modified by the term "about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/063,979 US8802658B2 (en) | 2012-05-14 | 2013-10-25 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/279,241 US20140249317A1 (en) | 2012-05-14 | 2014-05-15 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
PCT/US2014/050427 WO2015060924A1 (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3060220A1 true EP3060220A1 (en) | 2016-08-31 |
EP3060220A4 EP3060220A4 (en) | 2017-05-31 |
Family
ID=52993341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14856165.7A Withdrawn EP3060220A4 (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3060220A4 (en) |
JP (6) | JP6166471B2 (en) |
KR (3) | KR20190009428A (en) |
CN (2) | CN105960240B (en) |
AU (2) | AU2014340649C1 (en) |
CA (1) | CA2928350C (en) |
HK (1) | HK1257400A1 (en) |
IL (2) | IL245287A0 (en) |
MX (1) | MX2016005396A (en) |
MY (1) | MY176246A (en) |
SG (3) | SG11201603042TA (en) |
WO (1) | WO2015060924A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
KR20190009428A (en) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
WO2018079763A1 (en) | 2016-10-28 | 2018-05-03 | 三菱ケミカル株式会社 | Sizing agent for carbon fibers, aqueous dispersion of sizing agent for carbon fibers, and carbon fiber bundle to which sizing agent adheres |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1057488A4 (en) * | 1998-12-25 | 2003-10-22 | Toray Industries | Interleukin-6 production inhibitors |
GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
HUP0400096A2 (en) * | 2001-05-02 | 2004-04-28 | Novartis Ag. | Pharmaceutical uses of bisphosphonates |
US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
JP2006506365A (en) * | 2002-10-15 | 2006-02-23 | ノバルティス アクチエンゲゼルシャフト | Administration method of bisphosphonate |
WO2005005447A2 (en) * | 2003-07-03 | 2005-01-20 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
AR046773A1 (en) * | 2003-12-23 | 2005-12-21 | Novartis Ag | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES |
CA2769633C (en) * | 2009-07-31 | 2017-06-06 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
HUE035744T2 (en) * | 2010-02-06 | 2018-05-28 | Gruenenthal Gmbh | Crystallization method and bioavailability |
WO2012071517A2 (en) * | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
WO2013173330A1 (en) * | 2012-05-14 | 2013-11-21 | Antecip Bioventures Ii Llc | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
KR20190009428A (en) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
-
2014
- 2014-08-08 KR KR1020197001788A patent/KR20190009428A/en not_active Application Discontinuation
- 2014-08-08 WO PCT/US2014/050427 patent/WO2015060924A1/en active Application Filing
- 2014-08-08 CN CN201480069491.3A patent/CN105960240B/en active Active
- 2014-08-08 MX MX2016005396A patent/MX2016005396A/en unknown
- 2014-08-08 SG SG11201603042TA patent/SG11201603042TA/en unknown
- 2014-08-08 MY MYPI2016701480A patent/MY176246A/en unknown
- 2014-08-08 EP EP14856165.7A patent/EP3060220A4/en not_active Withdrawn
- 2014-08-08 SG SG10201609548UA patent/SG10201609548UA/en unknown
- 2014-08-08 KR KR1020167012645A patent/KR101739244B1/en active IP Right Grant
- 2014-08-08 SG SG10201800001VA patent/SG10201800001VA/en unknown
- 2014-08-08 JP JP2016526009A patent/JP6166471B2/en active Active
- 2014-08-08 CN CN201810150156.6A patent/CN108434154A/en active Pending
- 2014-08-08 AU AU2014340649A patent/AU2014340649C1/en active Active
- 2014-08-08 CA CA2928350A patent/CA2928350C/en active Active
- 2014-08-08 KR KR1020177013050A patent/KR101975687B1/en active IP Right Grant
-
2016
- 2016-04-21 IL IL245287A patent/IL245287A0/en unknown
-
2017
- 2017-02-07 AU AU2017200832A patent/AU2017200832A1/en not_active Abandoned
- 2017-06-22 JP JP2017121884A patent/JP6453387B2/en active Active
- 2017-08-23 IL IL254123A patent/IL254123A0/en unknown
-
2018
- 2018-12-12 JP JP2018232467A patent/JP6802245B2/en active Active
- 2018-12-26 HK HK18116608.0A patent/HK1257400A1/en unknown
-
2020
- 2020-11-26 JP JP2020196080A patent/JP7136487B2/en active Active
-
2022
- 2022-08-25 JP JP2022134019A patent/JP2022162105A/en active Pending
-
2024
- 2024-02-07 JP JP2024017350A patent/JP2024040304A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9616077B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US9616078B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
AU2013262995B2 (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
AU2014340649C1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
AU2014340649A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
WO2016172453A1 (en) | Pharmacodynamic effects after oral administration of zoledronic acid or related compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160517 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170428 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/20 20060101ALI20170421BHEP Ipc: A61K 31/675 20060101AFI20170421BHEP Ipc: A61P 29/00 20060101ALI20170421BHEP Ipc: A61P 19/02 20060101ALI20170421BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190211 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |